Pharmaxis (PXS) News Today → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free PXS Stock Alerts Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSyntara bolsters financial position with R&D tax incentiveproactiveinvestors.com.au - December 4 at 11:11 PMHere's Why Shareholders Should Examine Pharmaxis Ltd's (ASX:PXS) CEO Compensation Package More Closelyfinance.yahoo.com - November 21 at 5:31 PMFIVE at FIVE AU: ASX down 1.5% on Middle East fears; employment slowsproactiveinvestors.com.au - October 19 at 10:50 AMPharmaxis to focus on clinical-stage drug developmentproactiveinvestors.com.au - October 3 at 12:57 AMPharmaxis to undergo major company restructure and rebrand as Syntara; sells mannitol businessproactiveinvestors.com.au - October 3 at 12:57 AMPharmaxis to Sell Mannitol Respiratory Business As Part of 'Major' Restructuringmarketwatch.com - October 2 at 7:56 PMFIVE at FIVE AU: ASX gains as inflation easesproactiveinvestors.com.au - August 30 at 3:59 AMPharmaxis says majority of patients in fibrosis trial see significant improvementfinance.yahoo.com - July 13 at 12:55 PMPXS.AX - Pharmaxis Ltdfinance.yahoo.com - June 5 at 12:53 PMPharmaxis extends scarring collaboration after encouraging resultsproactiveinvestors.com - May 25 at 1:06 AMPharmaxis achieves 30% reduction in scar tissue with topical LOX inhibitor in Phase 1C study; extends UWA collaborationproactiveinvestors.com - May 24 at 12:25 AMPharmaxis Ltd (PXS.XA)finance.yahoo.com - May 21 at 12:43 AMPharmaxis adds combination treatment arm to Phase 2 myelofibrosis studyproactiveinvestors.com.au - April 11 at 11:50 PMPharmaxis to accelerate plans for myelofibrosis combination study after FDA talksproactiveinvestors.com - April 11 at 11:50 PMPharmaxis' PXS-5505 doubles response rate to standard therapy in blood cancer in preclinical studies; features in prestigious journalproactiveinvestors.com - March 23 at 2:01 AMPharmaxis Second Quarter 2023 Earnings: AU$0.008 loss per share (vs AU$0.01 loss in 2Q 2022)finance.yahoo.com - February 12 at 9:20 PMPharmaxis Ltd (PXS.AX)nz.finance.yahoo.com - January 28 at 1:42 PMPharmaxis strengthens board with appointment of experienced healthcare analyst Hashan De Silva as non-executive directorproactiveinvestors.com - January 15 at 11:29 PMPharmaxis secures almost A$5 million in research and development tax incentivesproactiveinvestors.com - January 9 at 12:25 AMPharmaxis' skin scarring study of its PXS-6302 asset now fully recruitedproactiveinvestors.com.au - December 20 at 10:53 PMPharmaxis appoints senior global pharma executive Dr Simon Green as a non-executive directorproactiveinvestors.com.au - December 13 at 11:13 PMPharmaxis cancer drug PXS-5505 profiled in two posters at American Society of Haematology Conferenceproactiveinvestors.com - December 12 at 9:04 PMPharmaxis receives interim data for Phase 2 cancer trialproactiveinvestors.com.au - October 19 at 2:28 AMPharmaxis welcomes positive interim data for Phase 2 cancer trialproactiveinvestors.com - October 19 at 2:28 AMLAST ORDERS: A light-hearted look at today’s market stuffmsn.com - October 18 at 9:48 AMPharmaxis CEO talks promising interim data from skin scarring studyproactiveinvestors.com - September 26 at 9:47 AMPharmaxis fields promising interim data from skin scarring treatment study assessing PXS-6302proactiveinvestors.com - September 25 at 11:42 PMPXS.AX - Pharmaxis Ltd. | Stock Price & Latest News | Reutersreuters.com - September 20 at 6:16 PMPharmaxis talks Parkinson's UK collaboration, A$5 million cash injectionproactiveinvestors.com - September 4 at 8:18 PMASX Health Stocks: Pharmaxis gets $5m to fund groundbreaking collaboration study of lead drug PXS‐4728msn.com - September 1 at 7:50 AMProactive news headlines including Kinetiko Energy, Boadicea Resources, American Rare Earths and Surefire Resourcesyahoo.com - September 1 at 2:29 AMPharmaxis to tackle Parkinson’s in “groundbreaking” clinical collaborationproactiveinvestors.com - September 1 at 2:29 AMPharmaxis lands US$5 million deal with global drug delivery specialistproactiveinvestors.com - August 5 at 2:07 AMArovella Therapeutics bolsters management experience with appointment of non-executive directorproactiveinvestors.com.au - June 30 at 10:39 PMPharmaxis appoints 20-year veteran as Chief Medical Officerproactiveinvestors.com - June 30 at 10:39 PMPharmaxis Ltd (ASX:PXS) insider upped their holding by 71% earlier this yearfinance.yahoo.com - June 6 at 12:37 AMGlobal Scar Treatment Market (2021 to 2029) - Share, Size, Trends and Industry Analysis Reportuk.news.yahoo.com - February 24 at 8:43 AMPharmaxis teams with renowned surgeon Fiona Wood for scar tissue trialproactiveinvestors.com - February 1 at 10:34 PMPharmaxis confident of capturing global market for scar reduction with first patients dosed in studyproactiveinvestors.com - January 31 at 1:41 AMPharmaxis discoveries to get a A$1.4 million boost to advance cancer and skin disease treatmentsproactiveinvestors.com.au - January 6 at 10:20 AMTrade Alert: The Independent Chairman of the Board Of Pharmaxis Ltd (ASX:PXS), Malcolm McComas, Has Just Spent AU$113k Buying 71% More Sharesfinance.yahoo.com - December 27 at 8:01 PMPharmaxis’ oversubscribed share purchase plan raises $2.6 millionproactiveinvestors.com.au - December 20 at 1:49 PMPharmaxis stocks rising with new drugs coming online in 2022, says brokerproactiveinvestors.com.au - December 6 at 6:13 AMPharmaxis bolsters balance sheet with $7.2 million placement and $2 million share purchase planproactiveinvestors.com - November 17 at 12:52 AMPharmaxis raising $9.2 million via Morgansafr.com - November 15 at 12:41 AMFDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancerfinance.yahoo.com - November 9 at 10:26 AMPharmaxis receives FDA clearance to progress cancer drug to Phase 2 study in liver cancerproactiveinvestors.com - November 9 at 12:27 AMPharmaxis receives approval for phase 2 study of its cancer drug in liver cancerproactiveinvestors.com - November 8 at 7:26 PMPharmaxis attracts A$0.53 price target in coverage initiation from MST Accessproactiveinvestors.com - November 7 at 10:26 PMShareholders May Be More Conservative With Pharmaxis Ltd's (ASX:PXS) CEO Compensation For Nowfinance.yahoo.com - October 27 at 7:40 PM Get Pharmaxis News Delivered to You Automatically Sign up to receive the latest news and ratings for PXS and its competitors with MarketBeat's FREE daily newsletter. Email Address AI Bubble Now at Critical Mass (Ad)Washington, D.C., has just issued its first round of new artificial-intelligence (“AI”) regulations. And a flood of additional AI bills is making its way through Congress. Nasdaq reports this could bring a screeching halt to the AI stock boom. Simply click here now to read The Big AI Die-Up. PXS Media Mentions By Week PXS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PXS News Sentiment▼0.000.60▲Average Medical News Sentiment PXS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PXS Articles This Week▼00▲PXS Articles Average Week Get Pharmaxis News Delivered to You Automatically Sign up to receive the latest news and ratings for PXS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TGIFF News Today FFNTF News Today ABSCF News Today ACRHF News Today ACRDF News Today ALEAF News Today LBTSF News Today AZFL News Today ERBB News Today AVTBF News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ASX:PXS) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharmaxis Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.